Werewolf Therapeutics (HOWL) EPS (Basic) (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed EPS (Basic) for 5 consecutive years, with -$0.36 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 5.26% to -$0.36 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.62, a 8.0% decrease, with the full-year FY2024 number at -$1.63, down 55.24% from a year prior.
  • EPS (Basic) was -$0.36 for Q3 2025 at Werewolf Therapeutics, up from -$0.4 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $5.97 in Q3 2021 to a low of -$83.36 in Q1 2021.
  • A 5-year average of -$4.52 and a median of -$0.39 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): soared 99.33% in 2022, then tumbled 166.67% in 2024.
  • Werewolf Therapeutics' EPS (Basic) stood at $0.95 in 2021, then plummeted by 140.0% to -$0.38 in 2022, then rose by 13.16% to -$0.33 in 2023, then crashed by 39.39% to -$0.46 in 2024, then increased by 21.74% to -$0.36 in 2025.
  • Per Business Quant, the three most recent readings for HOWL's EPS (Basic) are -$0.36 (Q3 2025), -$0.4 (Q2 2025), and -$0.4 (Q1 2025).